Closed · RFA-DC-11-002 · CFDA 93.173 · Discretionary
Identification of Immune-Mediated Causes of Sensorineural Hearing Loss (R21/R33)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- June 8, 2011
- Close date
- -
- Expected awards
The verdict
Identification of Immune-Mediated Causes of Sensorineural Hearing Loss (R21/R33) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.173
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Identification of Immune-Mediated Causes of S… is closed (last close June 8, 2011). The parent program page for CFDA 93.173 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed June 8, 2011
Instrument
Grant
Description
Purpose. The purpose of this FOA is to encourage submission of milestone-driven interdisciplinary Exploratory/Developmental Phased Innovation (R21/R33) research proposals designed to further our understanding of the mechanism, etiology, and pathophysiology of immune mediated sensorineural hearing loss (IMSNHL). Applications considered responsive include studies of 1) ear organ-specific autoimmune sensorineural hearing loss - i.e. autoimmune inner ear disease (AIED), 2) sudden sensorineural hearing loss attributable to AIED, as well as 3) sensorineural hearing loss associated with systemic autoimmune disease. Proposals primarily involving human subjects/tissues will be given highest priority. The human health goal of this FOA is the ultimate translation of the research findings into clinical biomarkers, new diagnostic tests with high sensitivity, specificity and positive predictive value, and the development of therapies that preserve natural hearing. Mechanism of Support. This FOA will utilize the R21/R33 Exploratory/Developmental Phased Innovation grant mechanism. Funds Available and Anticipated Number of Awards. NIDCD has set aside $700K in FY2011 and $1.3M in FY2012 in anticipation of 2-3 awards per application cycle.
Market-open applicant set · includes for-profit door
The eligibility set for Identification of Immune-Mediated Causes of S… includes a for-profit door among 10 printed types (State governments; Public / state-controlled institutions of higher education; Federally recognized tribal governments; Native American tribal organizations (other than Federally recognized tribal governments); +6 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Health (HL). Only 91 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).
- Code 00
- State governments
- Code 06
- Public / state-controlled institutions of higher education
- Code 07
- Federally recognized tribal governments
- Code 11
- Native American tribal organizations (other than Federally recognized tribal governments)
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Research on Healthcare Costs, Quality and Outcomes
U.S. Department of Health and Human Services
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Identification of Immune-Mediated Causes of S… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.173 may publish future NOFOs under the same assistance listing. Open program
- Research on Healthcare Costs indexes 118 Grants.gov listings in this extract. Program profile
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |